Ozawa Yuichi, Suda Takafumi, Nagata Toshi, Hashimoto Dai, Nakamura Yutaro, Enomoto Noriyuki, Inui Naoki, Koide Yukio, Nakamura Hirotoshi, Chida Kingo
Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Am J Respir Cell Mol Biol. 2009 Oct;41(4):440-8. doi: 10.1165/rcmb.2008-0446OC. Epub 2009 Feb 6.
Effective protective immunity against respiratory infections with intracellular pathogens requires pathogen-specific cytotoxic T cells (CTL) in the lung. However, vaccines that induce pathogen-specific CTL in the lung are poorly explored. Dendritic cells (DC) have increasingly been exploited as vaccines against infections. However, few studies have investigated the ability of mucosal DC vaccines to elicit protective CTL responses in the lung. Our objective was to develop an efficacious mucosal DC vaccine to generate protective CTL against respiratory infections with intracellular pathogens. Bone marrow-derived DC (BM-DC) pulsed with a single immunodominant CTL epitope, listeriolysin O (LLO) 91-99, of Listeria monocytogenes (LM) were intratracheally administered into mice. The frequency and function of epitope-specific CTL in mediastinal lymph nodes (MLN) and spleen were assessed for their ability to protect against LM infection. After intratracheal administration, lipopolysaccharide (LPS)-treated LLO 91-99-loaded BM-DC (LPS-LLO DC) more frequently migrated to MLN than LPS-untreated LLO 91-99-loaded BM-DC (LLO DC). Using tetrameric H2-K(d)/LLO 91-99 peptide complex, specific CD8(+) T cells were found in MLN as well as the spleen in LPS-LLO DC-immunized mice, but not in LLO-DC-immunized mice. Both MLN and spleen cells obtained from LPS-LLO DC-immunized mice produced large amounts of IFN-gamma in response to LLO 91-99 with high epitope-specific CTL activities. Vaccination with LPS-LLO DC, but not LLO DC, protected mice against lethal respiratory infection with LM. These data suggest that mucosal vaccination with LPS-treated immunodominant CTL epitope-loaded DC is a promising strategy for generating protective CTL against respiratory infections with intracellular pathogens.
对细胞内病原体引起的呼吸道感染产生有效的保护性免疫需要肺内具有病原体特异性的细胞毒性T细胞(CTL)。然而,能在肺内诱导病原体特异性CTL的疫苗尚未得到充分研究。树突状细胞(DC)越来越多地被用作抗感染疫苗。然而,很少有研究调查黏膜DC疫苗在肺内引发保护性CTL反应的能力。我们的目标是开发一种有效的黏膜DC疫苗,以产生针对细胞内病原体引起的呼吸道感染的保护性CTL。用单核细胞增生李斯特菌(LM)的单一免疫显性CTL表位李斯特菌溶血素O(LLO)91 - 99脉冲处理的骨髓来源DC(BM - DC)经气管内给予小鼠。评估纵隔淋巴结(MLN)和脾脏中表位特异性CTL的频率和功能,以确定其预防LM感染的能力。经气管内给药后,经脂多糖(LPS)处理的负载LLO 91 - 99的BM - DC(LPS - LLO DC)比未用LPS处理的负载LLO 91 - 99的BM - DC(LLO DC)更频繁地迁移至MLN。使用四聚体H2 - K(d)/LLO 91 - 99肽复合物,在LPS - LLO DC免疫的小鼠的MLN以及脾脏中发现了特异性CD8(+) T细胞,而在LLO - DC免疫的小鼠中未发现。从LPS - LLO DC免疫的小鼠获得的MLN和脾脏细胞在对LLO 91 - 99产生反应时产生大量干扰素 - γ,具有高表位特异性CTL活性。用LPS - LLO DC而非LLO DC进行疫苗接种可保护小鼠免受LM致死性呼吸道感染。这些数据表明,用经LPS处理的负载免疫显性CTL表位的DC进行黏膜疫苗接种是产生针对细胞内病原体引起的呼吸道感染的保护性CTL的一种有前景的策略。